PubMed Health⌕ Search

Biomedical subjects

M Passeri

Publications and source records attributed to M Passeri.

At least 109 records · Page 6Linked to original sources
PubMed1987

Nicotinic and M1-, M2-muscarinic cholinergic control of ACTH response to insulin-induced hypoglycaemia in man.

The possible mediation of muscarinic and/or nicotinic-cholinergic receptors in the response of ACTH to insulin-induced hypoglycaemia was evaluated in 18 normal men. Subjects were tested with the insulin (0.15 U/kg) tolerance test (ITT) in basal conditions and in the presence of the M1- and M2-muscarinic antagonist atropine (600 micrograms iv just before insulin injection (time 0) plus 600 micrograms 20 min later in 6 subjects) or the M1-muscarinic receptor blocker pirenzepine (40 mg iv 10 min before ITT or 20 mg at time 0 plus 30 mg at time 20 in 6 subjects). The remaining 6 men were treated with the nicotinic receptor antagonist trimethaphan (0.3 mg/min x 30 min before ITT). ACTH rose 4.7 times in response to hypoglycaemia. The ACTH response to hypoglycaemia did not change after pirenzepine administration, whereas it was significantly increased by atropine and decreased by trimethaphan treatment. These data indicate that nicotinic and muscarinic (M2 but not M1) receptors participate in a different manner in the regulation of the hypoglycaemia-induced ACTH release.

Adrenocorticotropic Hormone↗
PubMed1986

Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study.

In this paper we present the results of a 12-month double-blind clinical multicenter study assessing the effects of synthetic salmon calcitonin (CT) administration in a group of white postmenopausal osteoporotic women. Treated patients were given 100 MRC units of synthetic salmon CT injected i.m. in the morning every other day. Control patients received a placebo injection. All patients received 500 mg of elementary calcium p.o., b.i.d. Bone mineral content (BMC) was measured at the extreme distal radius of the nondominant arm by a dual photon bone densitometer which utilizes two radionuclides, 241Am and 125I, with energies of about 60 keV and 30 keV respectively. Biochemical parameters of calcium-phosphorus metabolism were also measured. After 12 months of treatment a significant mean increment of BMC and nondialyzable OHPr/creatinine values and a significant decrease of total OHPr/creatinine values were observed in the treated group, while controls showed a significant decrease in BMC values. These results, together with the observation that in some patients the decrease in total OHPr/creatinine values was not accompanied by an increment of BMC, show that long-term salmon CT treatment may be of benefit in postmenopausal osteoporosis and that the effects of CT on bone mass may be due not only to the inhibition of bone resorption but also to the stimulation of bone formation.

Aged↗
PubMed1986

The pathophysiology of calcitonin in man.

It is generally accepted that calcitonin (CT) induces a decrement in cytosolic Ca++, and an increase of cAMP in target cells of several organs and tissues. This happens particularly in bone, where osteoclast activity and size decreases, along with the widely-known hypocalcaemic and hypophosphoraemic effect of the hormone. The physiological role of CT appears to be of importance in pregnancy and perhaps in infancy, when it antagonizes possible excessive bone loss. Some experimental evidence shows that CT may be involved in the maintenance of post-meal calcaemia. It is not yet established whether paucity of CT plays any important role in the pathogenesis of pathological conditions such as post-menopausal and senile osteoporosis.

Adult↗
PubMed1985

Prolactin dynamics in patients with non-secretin tumours of the hypothalamic-pituitary region.

Twenty-four patients with non-secreting tumours of the hypothalamic-pituitary region, diagnosed by radiographic procedures and confirmed at surgery, were examined before and after the surgical treatment to establish a correlation between Prl responsiveness to dynamic tests and the location of pathological tissue. Three groups of patients were identified. In 10 patients with an intrasellar tumour (group I), Prl had a positive response to TRH, metoclopramide (MCP), and nomifensine (NOM), both pre- and postoperatively. In 4 patients with tumours located entirely in the hypothalamus (group II), Prl responded to TRH, but remained unresponsive to MCP and NOM. Only a partial normalization of the Prl responses was obtained after surgery. Finally, 10 patients had an intra- and extrasellar tumour (group III). In 8 of them Prl responded to TRH, but the increment was lesser than that observed in hypothalmic tumours. Prl did not respond to MCP and NOM. After surgery, Prl responsiveness reappeared in some patients (6 after TRH, 4 after MCP, 3 after NOM). In 2 patients with extensive pituitary damage, Prl did not respond to all dynamic tests pre- or postoperatively. In conclusion, Prl dynamic tests are a reliable tool for studying the altered control of Prl secretion in these patients, since plasma Prl stems from only normal lactotropes surrounding the tumoural tissue. The location of the tumour has a key role in influencing the pattern of Prl response to direct and indirect dynamic tests.

Adenoma↗
PubMed1985

Double-blind multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis.

A randomized double-blind multicentre clinical trial was carried out to verify the effectiveness and tolerance of S-adenosylmethionine (SAMe) versus ibuprofen in 150 patients with hip and/or knee osteoarthritis. Both drugs were given orally 400 mg thrice daily for 30 days. SAMe exhibited a slightly more marked activity than the reference drug in the management of the various painful manifestations of the joint disease. Minor side-effects developed in five patients of SAMe group, and in 16 patients of ibuprofen group. No drop-outs occurred. No changes were observed in the routine laboratory tests.

Aged↗
PubMed1985

Calcitonin deficit syndrome in thyroidectomized patients.

The results of a study carried out on 10 patients who underwent total or subtotal thyroidectomy to determine the effects of a prolonged deficit in calcitonin on bone turnover, are reported. The following parameters were evaluated: serum calcium and phosphate, serum alkaline phosphatase, urinary hydroxyproline, serum iPTH, serum iCT and bone mineral content (BMC) of the distal radius. In ten patients controlled 24 months after surgery, a lowering in circulating iCT levels was noted together with a significant decrease in BMC. These observations while supporting the theory that a CT deficit can determine osteoporosis, suggest that further consideration should be given to substitutive therapies for totally and subtotally thyroidectomized patients.

Bone and Bones↗
PubMed1984

Sulphinpyrazone in cardiovascular elderly azotemic patients: a proposal of a 'guided' incremental dose schedule.

Renal tolerability of a guided incremental dose schedule of sulphinpyrazone was evaluated in an open study of 2-month duration, performed in twenty-one cardiovascular elderly azotemic patients (thirteen males, eight females; mean age: 79 years, S.D.: 7 X 3 years). Starting dosage was 200 mg per day; daily dosage was then increased, every 4 days, by 200 mg or kept constant for another 4 days, according to each patient's basal renal function, up to the maintenance dose: 800 mg/day. Eighty-one per cent of the patients followed a successful incremental pathway, 9% kept a constant daily dosage of 200 mg for 8 days, reaching then the maintenance daily dose without any problems. Nine per cent withdrew at 200 mg/day because renal function deteriorated at two consecutive visits. Renal function of the patients who completed the study significantly improved (two-way ANOVA, p less than 0.01). General tolerability was good. The proposed incremental dose schedule of sulphinpyrazone can be successfully used in the treatment of cardiovascular elderly azotemic patients.

Aged↗
PubMed1983

[Dihydroergotoxine mesylate in the treatment of senile cerebral insufficiency. Result of a long-term multicenter double-blind clinical trial with a placebo].

Many controlled double-blind clinical trials against placebo and other drugs have clearly demonstrated the activity of dihydroergotoxine mesylate (DHT) on some symptoms of chronic senile cerebral insufficiency (CSCI). In spite of this, there is still some controversy about the usefulness of DHT for treatment of CSCI, as it seems to be hard to transpose the results of these studies to treatment of a population with DHT. Trying to overcome this criticism, a multicenter double-blind, placebo-controlled long-term (1 year) clinical trial has been planned, using very simple criteria for patient selection and easy to use assessment devices. Fifty two centres distributed throughout Italy were invited and 40 took active part in the study. The present report deals with data collected for analysis on Aug. 31, 1982. On this date 559 patients entered the study and 458 were under treatment (229 on DHT 1.5 mg t.i.d. and 229 on placebo). 101 patients dropped out (48 on DHT and 53 on placebo). 388 patients (195 on DHT and 193 on placebo) had completed 6 months and 204 (111 on DHT and 93 on placebo) had completed 1 year of treatment. The data from patients who completed 6 and 12 months of treatment period were analyzed statistically using Student t tests for paired and unpaired data, the large number of patients being adequate protection against any non normality in the distribution of the data. Differences with 2P values of 0.01 or less were considered significant.(ABSTRACT TRUNCATED AT 250 WORDS)

Aged↗
PubMed1983

[Vitamin E in geriatric physiopathology].

Vitamin E can modify some of the metabolic aspects of ageing (free radicals, deficiency of protein synthesis etc.) and ameliorate the functionality of the most important body organs, of vascular and muscolo-skeletal system and metabolism. The effects of tocopherols on the glyco-lipid metabolism, as well as its hypocholesterolemic and antithrombophylic activities can positively protect the organism from the atherosclerotic damage. Vitamin E has been demonstrated to exert some effect on the maintainance of bone matrix trophysm.

Aged↗